The impact of DT2216 was minimal to the majority of myeloid cell populations in tumor-bearing mice, including granulocytic or monocytic MDSC (CD11b+Ly6G+ G-MDSC or CD11b+Ly6C+Ly6G− M-MDSC), macrophages (F4/80+), dendritic cells (CD11c+MHCII+ DC), or CD8+ DCs, with the exception of DC where DT02216 treatment led to slightly decreased TI-DC population (Supplementary Fig. 8a–d). Here, CD8A is linked to neoplasm.